Back to Search Start Over

Neuromodulatory effect of vardenafil on aluminium chloride/d-galactose induced Alzheimer's disease in rats: emphasis on amyloid-beta, p-tau, PI3K/Akt/p53 pathway, endoplasmic reticulum stress, and cellular senescence.

Authors :
Awad, Heba H.
Desouky, Mahmoud A.
Zidan, Alaa
Bassem, Mariam
Qasem, Amaal
Farouk, Mona
AlDeab, Haidy
Fouad, Miral
Hany, Cherry
Basem, Nada
Nader, Rita
Alkalleny, Ashrakat
Reda, Verina
George, Mina Y.
Source :
Inflammopharmacology. Oct2023, Vol. 31 Issue 5, p2653-2673. 21p.
Publication Year :
2023

Abstract

Dysregulation of protein homeostasis, proteostasis, is a distinctive hallmark of many neurodegenerative disorders and aging. Deleteriously, the accumulation of aberrant proteins in Alzheimer's disease (AD) is accompanied with a marked collapse in proteostasis network. The current study explored the potential therapeutic effect of vardenafil (VAR), a phosphodiesterase-5 inhibitor, in AlCl3/d-galactose (d-gal)-induced AD in rats and its possible underlying mechanisms. The impact of VAR treatment on neurobehavioral function, hippocampal tissue architecture, and the activity of the cholinergic system main enzymes were assessed utilizing VAR at doses of 0.3 mg/kg and 1 mg/kg. Additionally, the expression level of amyloid-beta and phosphorylated tau proteins in the hippocampus were figured out. Accordingly, VAR higher dose was selected to contemplate the possible underlying mechanisms. Intriguingly, VAR elevated the cyclic guanosine monophosphate level in the hippocampus and averted the repressed proteasome activity by AlCl3/d-gal; hence, VAR might alleviate the burden of toxic protein aggregates in AD. In addition, a substantial reduction in the activating transcription factor 6-mediated endoplasmic reticulum stress was demonstrated with VAR treatment. Notably, VAR counteracted the AlCl3/d-gal-induced depletion of nuclear factor erythroid 2-related factor 2 level. Moreover, the anti-senescence activity of VAR was demonstrated via its ability to restore the balance of the redox circuit. The modulation of phosphatidylinositol-3-kinase/protein kinase B/p53 pathway and the reduction of nuclear factor kappa B level, the key regulator of senescence-associated secretory phenotype mediators release, with VAR treatment were also elucidated. Altogether, these findings insinuate the possible therapeutic benefits of VAR in AD management. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09254692
Volume :
31
Issue :
5
Database :
Academic Search Index
Journal :
Inflammopharmacology
Publication Type :
Academic Journal
Accession number :
172311858
Full Text :
https://doi.org/10.1007/s10787-023-01287-w